Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume

Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 662,200 shares of ATRA short. 17.61% of Atara Biotherapeutics' shares are currently sold short. Learn More on Atara Biotherapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 7.0. Learn More on Atara Biotherapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Atara Biotherapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.61% of Atara Biotherapeutics' floating shares are currently sold short.

Atara Biotherapeutics saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 662,200 shares, a drop of 0.7% from the previous total of 666,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Atara Biotherapeutics currently has issued a total of 5,859,000 shares. Some of Atara Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atara Biotherapeutics currently has a public float of 3,760,000 shares.

17.61% of Atara Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atara Biotherapeutics: Fate Therapeutics, Inc. (14.41%), 4D Molecular Therapeutics, Inc. (12.13%), Puma Biotechnology, Inc. (7.39%), Protara Therapeutics, Inc. (11.25%), ProQR Therapeutics (1.10%), Tiziana Life Sciences Ltd (1.46%), Nkarta, Inc. (11.18%), Lyell Immunopharma, Inc. (4.52%), scPharmaceuticals Inc. (10.66%), Larimar Therapeutics, Inc. (9.14%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is April, 15 2025.